A total of 41 patients (41 eyes, 11 males and 30 females) with myopia CNV were included
in this study. The mean age of these patients was 52.93±14.22 (22 to 77 years), and
the mean time of intravitreal injection was 1.88±0.87. 22 eyes were injected with Ranibizumab, and 19 eyes were injected with Conbercept.
The mean LogMAR BCVA was 0.56±0.30 at baseline and 0.41±0.27, 0.33±0.27, 0.31±0.26
and 0.30±0.27 at 1, 2, 3 and 6 months follow-up, respectively (Fig. 1). The difference
between LogMAR BCVA at baseline and at 1, 2, 3 and 6 months follow-up was statistically
significant (F=6.848，P<0.05). The intravitreal anti-VEGF therapy improved the logMAR
BCVA at 1-month (P=0.017), 2-month (P=0.001), 3-month (P=0.000) and 6-month follow-ups
Superficial vessel density of retina
The mean superficial vessel density of retina was 42.24±5.90% at baseline and 43.43±6.11%,
42.08±5.85%, 41.12±6.28% and 41.08±5.72% at 1, 2, 3 and 6 months follow-up, respectively.
There was no significant difference before and after the treatment (F=1.071，P>0.05).
Deep vessel density of retina
The mean deep vessel density of retina was 46.63±5.53% at baseline and 46.24±5.88%,
46.31±4.77%, 46.55±5.47% and 46.16±5.85% at 1, 2, 3 and 6 months follow-up, respectively.
There was no significant difference between them (F=0.055，P>0.05).
The mean FAZ was 0.253±0.090 mm²at baseline and 0.258±0.091 mm², 0.261±0.079 mm²,
0.271±0.093 mm²and 0.266±0.097 mm²at 1, 2, 3 and 6 months follow-up, respectively. There was no significant difference
between them (F=0.119，P>0.05).
The mean CMT was 289.15±74.76 μm at baseline and 256.44±61.77 μm, 258.32±55.70 μm,
254.05±53.29 μm and 252.59±62.21 μm at 1, 2, 3 and 6 months follow-up, respectively
(Fig. 2). The difference between the CMT at baseline and at each follow-up was statistically
significant (F=2.489，P<0.05). However, there was no difference in the values of CMT
between 1, 2, 3 and 6 months follow-up.
The area and flow area of CNV lesion
The mean area of CNV lesion was 0.645±0.773 mm² at baseline and 0.356±0.426 mm2, 0.318±0.377 mm², 0.355±0.433 mm² and 0.320±0.399 mm² at 1, 2, 3 and 6 months follow-up,
respectively (Fig. 3). The mean flow area of CNV lesion was 0.494±0.556 mm² at baseline
and 0.264±0.306 mm², 0.255±0.293 mm², 0.261±0.313 mm²and 0.234±0.295 mm² at 1, 2,
3 and 6 months follow-up, respectively (Fig. 4). The difference between the area (F=3.125，P<0.05)
and flow area (F=3.558，P<0.05) of the CNV lesion at baseline and at each follow-up
was statistically significant. However, there was no difference between 1, 2, 3 and
6 months follow-up. Although the area of the CNV lesion reduced after injection, in
most patients (95.12%), it didn't disappear even when its activity had been controlled.
The mean reduction ratio of lesions was 50.32% (7.07% to 100%). In only two cases,
100% lesion regression was observed (4.88%).
We divided the patients into two groups according to the CNV area before treatment
(＞0.5mm²and ≤0.5mm²). The reduction ratio in the two groups was compared using independent t-test
(t=2.136, P=0.042). The reduction ratio in the group with preoperative CNV area ＞0.5
mm² was smaller than the other group.
The Pearson correlation analysis showed the negative correlation between the area
of the CNV lesion and the reduction ratio（r=-0.380，P=0.042) and between the flow lesion
area and the reduction ratio (r=–0.402, P=0.030). It means the bigger the CNV lesion is, the lower is the reduction
ratio. There is no significant difference between the reduction ratio and other factors,
such as age, LogMAR BCVA and CMT before treatment and the improvement of BCVA.
Case 1. In a 33-year-old female with myopia CNV in the right eye, the refraction of myopia
was –7.0 D and the LogMAR BCVA was 0.1. The lesion disappeared completely after one intravitreal
Ranibizumab injection, and the LogMAR BCVA was improved to 0 (Fig. 5).
Case 2. In a 58-year-old female with myopia CNV in the right eye, the refraction of myopia
was –9.5 D and the LogMAR BCVA was 0.7. The lesion just became smaller but still existed
after three times intravitreal Conbercept injection, and the LogMAR BCVA was improved
to 0.15 (Fig. 6).